About the Leaders of IBDLinka,b

Learn more about the global committee of gastroenterologists (GIs) that is leading the IBDLink global community and its efforts to support the clinical needs of HCPs and the patients under their care.

Jean-FrédéricColombel, MD, IBDLink Leadership
Professor of Medicine, Gastroenterology
Icahn School of Medicine at Mount Sinai
The Mount Sinai Health System
New York, New York, USA

Jean-Frédéric Colombel was Professor of Medicine and head of Department of Gastroenterology at CHU Lille in France and president of the GETAID (Groupe d’Etudes Thérapeutiques des Affections Inflammatoires Digestives), president of ECCO (European Crohn’s and Colitis Organization) and chair of the International Organization for Inflammatory Bowel Disease (IOIBD). He moved to Icahn School of Medicine at Mount Sinai, New York, in 2013 to become Director of the Susan and Leonard Feinstein IBD Clinical Center and the Leona and Harry B. Helmsley Charitable Trust IBD Center. He is the author or co-author of more than 700 peer-reviewed articles, books, and book chapters. He is associate editor of Gastroenterology. His research interests cover all fields of inflammatory bowel disease.

Silvio Danese, MD, IBDLink Leadership
Head, IBD Center
Department of Gastroenterology Humanitas Research Hospital
Milan, Italy

Silvio Danese, MD, is a gastroenterologist at the Istituto Clinico Humanitas in Milan, Italy, which is associated with the University of Milan. He is head of the Inflammatory Bowel Disease (IBD) Center. Dr Danese trained in gastroenterology at Policlinico Gemelli, Rome, Italy, and graduated with a doctorate degree, working in Dr Claudio Fiocchi’s laboratory at Case Western Reserve University in Cleveland, Ohio, USA.

Dr Danese’s main research interest is the investigation of the fundamental mechanisms underlying IBD pathogenesis, while his daily clinical activity is related to IBD patient care. He is actively involved in many international clinical trials in IBD-related areas and has published more than 200 papers in several journals, including New England Journal of Medicine, Gastroenterology, Gut, Journal of Clinical Investigation, Nature, and Nature Immunology.

Dr Danese is a member of many organizations related to the field of IBD, including the European Crohn´s and Colitis Organisation (ECCO), where he serves as secretary, and the International Organization for the Study of Inflammatory Bowel Diseases (IOIBD), where he holds the position of scientific secretary. He also sits on the editorial boards of Gut and Alimentary Pharmacology & Therapeutics, and is associate editor for Journal of Crohn’s and Colitis.

Geert D’Haens, MD, PhD, IBDLink Leadership
Professor of Inflammatory Intestinal Diseases
University of Amsterdam’s Faculty of Medicine
Amsterdam, The Netherlands

Geert D’Haens, MD, PhD, is professor of inflammatory intestinal diseases at the University of Amsterdam, The Netherlands, where he is also head of the Academic Medical Centre–IBD Unit. Dr D’Haens serves as director of gastroenterology at the Imelda GI Research Centre and as a consultant gastroenterologist for IBD, Section of Gastroenterology and Endoscopy, at the University Hospital Gasthuisberg, Leuven, Belgium.

Dr D’Haens founded and led the Imelda GI Clinical Research Centre, where clinical testing of many new medications for IBD and colorectal cancer have been conducted. He serves as secretary of the European Crohn’s and Colitis Organisation. In addition, he was president of the Flemish Society of Gastroenterology and cofounder of the European Crohn's and Colitis Organisation. Dr D’Haens is scientific secretary for the International Organisation for Inflammatory Bowel Disease (IOIBD) and chairman of its clinical trials task force.

Among Dr D'Haens’ main research interests are IBD, mucosal immunology, gastrointestinal endoscopy, and immunosuppression. He has published more than 120 articles in peer-reviewed journals and 27 chapters in medical textbooks.

Axel Dignass, MD, PhD, IBDLink Leadership
Director, Department of Medicine
Agaplesion Markus Hospital and Goethe University
Frankfurt am Main, Germany

Axel Dignass, MD, PhD, is director of the Department of Medicine I, and professor of medicine and gastroenterology at the Agaplesion Markus Hospital, Goethe University, in Frankfurt am Main, Germany. Prof Dr Dignass was trained in internal medicine and gastroenterology at the University of Essen, Germany, and at the Gastrointestinal Unit of Massachusetts General Hospital and Harvard Medical School in Boston, Massachusetts, USA. He is a specialist in internal medicine, gastroenterology, nutrition medicine, medical oncology, and proctology.

Prof Dr Dignass’ research interests focus on IBD, anti-inflammatory, immunosuppressive, and biologic therapy, anemia in IBD, small-bowel transplantation, molecular mechanisms of intestinal wound healing and cell migration, medical guidelines, and medical education.

Prof Dr Dignass has authored more than 185 publications in international peer-reviewed journals, more than 850 abstracts, and numerous books and book chapters. He is a member of the editorial board of the Journal of Crohn’s and Colitis, and acts as reviewer for several scientific journals and societies. Prof Dr Dignass has been education officer and a governing board member of the European Crohn’s and Colitis Organisation (ECCO), and treasurer and a governing board member of the German Society for Digestive Diseases and Metabolism. He also serves on the National Societies Committee and is chair of the guideline taskforce of United European Gastroenterology. Prof Dr Dignass is an honorary member of ECCO and a member of the International Organization of Inflammatory Bowel Diseases.

Iris Dotan, MD, IBDLink Leadership
Associate Professor of Medicine,
Head of the IBD Center
Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine
Tel Aviv, Israel

Iris Dotan, MD, is head of the Inflammatory Bowel Disease Center at the Tel Aviv Sourasky Medical Center in Tel Aviv, Israel, a tertiary referral center for patients with IBD. Prof Dr Dotan received her medical degree from the Sackler Faculty of Medicine at Tel Aviv University. Her post-doctoral fellowship, focused on intestinal epithelial cell biology, was completed at the Immunobiology Center at Mount Sinai Medical Center in New York, New York, USA. Prof Dr Dotan is a specialist in internal medicine, gastroenterology, and liver diseases.

Prof Dr Dotan’s clinical and research interests focus on patient stratification as a basis for improved patient care, prevention of complications, and a future cure for IBD. She has expertise in the use of biologics and novel therapies for IBD, and the follow up of patients with ulcerative colitis before and after restorative proctocolectomy pouch surgery in a comprehensive, multidisciplinary pouch clinic.

In addition, Prof Dr Dotan conducts translational research in mucosal immunology focusing on the interactions of mucosal lymphocytes with their environment, specifically epithelial cell-derived mediators and chemokines. She first described the new antiglycan antibodies and their relevance to Crohn’s disease a decade ago and is investigating the role of glycans in intestinal immune responses.

Marla Dubinsky, MD, IBDLink Leadership
Professor of Pediatrics and Medicine
Chief of Pediatric Gastroenterology, Hepatology and Nutrition
Co-Director of the Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center
Icahn School of Medicine at Mount Sinai
New York, New York, USA

Marla Dubinsky, MD, is professor of pediatrics, chief of pediatric gastroenterology, hepatology and nutrition, and co-director of the Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center at the Icahn School of Medicine at Mount Sinai in New York, New York. Dr Dubinsky received her medical degree from Queen’s University in Ontario, Canada. She completed her pediatric residency at Alberta Children’s Hospital in Calgary, Alberta, Canada, and her clinical fellowship in gastroenterology and nutrition at Sainte-Justine Hospital at the University of Montreal in Quebec, Canada. She completed her research fellowship in inflammatory bowel disease at Cedars-Sinai Medical Center in Los Angeles, California, USA, where she then served as director of the Pediatric Inflammatory Bowel Disease Center before moving to the Icahn School of Medicine.

Among Dr Dubinsky’s primary research focuses are the influence of genetics and immune responses on the variability in clinical presentations, treatment responses, and prognosis of early-onset inflammatory bowel disease (IBD). Her other interests include the effect of IBD on fertility and pregnancy. She has lectured widely nationally and internationally and published in 83 peer-reviewed journals including Gastroenterology, Journal of Pediatric Gastroenterology and Nutrition, Inflammatory Bowel Diseases, and American Journal of Gastroenterology.

Dr Dubinsky also currently sits on the editorial boards of several leading journals, including Gastroenterology, American Journal of Gastroenterology, and Nature Clinical Practice Gastroenterology & Hepatology.

Brian G. Feagan, MD, FRCPC, IBDLink Leadership
Director, Robarts Clinical Trials
Professor, Department of Medicine, Epidemiology, and Biostatistics
University of Western Ontario
London, Ontario, Canada

Brian G. Feagan, MD, serves as director of the Robarts Clinical Trials Juvenile Diabetes Research Foundation Canadian Clinical Trial Network Clinical Operations Centre at Western University in London, Ontario, Canada. He completed a medical degree at Western University in London, Ontario. His post-doctoral training included residency in the Department of Medicine and a clinical fellowship in the Division of Gastroenterology at Western University.

A fellow of the Royal College of Physicians and Surgeons of Canada, Dr Feagan holds membership in the Canadian and American Association of Gastroenterology, the American College of Gastroenterology, the College of Physicians and Surgeons of Ontario, and Crohn’s and Colitis Foundation of Canada.

Dr Feagan’s research efforts focus on the design and implementation of randomized controlled trials of therapy for inflammatory bowel disease, and he has been the principal investigator on numerous large-scale randomized clinical trials. Dr Feagan received numerous awards at Western University

In addition to publishing extensively in the peer-reviewed literature, Dr Feagan is a reviewer for the New England Journal of Medicine, Gastroenterology, American Journal of Gastroenterology, and several other journals. He has authored book chapters and served as editor for several books, including Evidence-Based Gastroenterology and Hepatology (2010, third edition). In 1997, Dr Feagan became director of Robarts Clinical Trials at the Robarts Research Institute of Western University.

Ailsa Hart, BMBCh, PhD, IBDLink Leadership
Director of St. Mark’s Hospital Inflammatory Bowel Disease Unit
St. Mark’s Hospital
London, United Kingdom

Ailsa Hart, BMBCh, PhD, is director of St. Mark’s Hospital Inflammatory Bowel Disease Unit and honorary senior clinical lecturer at Imperial College, both in London, UK. Dr Hart studied medicine at Oxford University and was awarded a first class honors degree, together with the George Pickering Prize for Medicine and Surgery proxime accessit and additional prizes for outstanding achievements. She holds membership in the Royal College of Physicians and trained in gastroenterology and general internal medicine in London.

Dr Hart’s clinical work covers the spectrum of gastrointestinal diseases, with a particular interest in IBD, Crohn’s disease, and ulcerative colitis. Her research interests focus on intestinal immunology and bacteriology, aiming to further understand the pathogenesis of inflammatory intestinal disorders via clinical trials in IBD and translational research. She has published more than 100 papers and book chapters, and 2 books including, Inflammatory Bowel Disease–an Evidence-based Practical Guide.

Dr Hart has links with laboratories within Imperial College, particularly the Antigen Presentation Research Group, which focuses on human intestinal dendritic cells and their role in the immune response. She has piloted fecal transplantation as a treatment for refractory pouchitis, funded by the Eli and Edyth Broad Foundation.

Among other professional associations, Dr Hart is a member of the clinical committee of the European Crohn’s and Colitis Organisation (ECCO); she is on the IBD Clinical Research Group Committee for the British Society of Gastroenterology, and is UK patient public involvement lead for gastroenterology in the Clinical Research Network (CRN). Dr Hart collaborates widely across the UK particularly within the UK IBD Genetics Consortium and is a member of the International Organisation for IBD (IOIBD).

Gary Lichtenstein, MD, IBDLink Leadership
Director, Center for Inflammatory Bowel Disease
University of Pennsylvania School of Medicine
Philadelphia, Pennsylvania, USA

Gary Lichtenstein, MD, is director of the Inflammatory Bowel Disease Center, and professor of medicine in the Gastrointestinal Division of the Department of Medicine, at the Hospital of the University of Pennsylvania and the University of Pennsylvania School of Medicine in Philadelphia, Pennsylvania, USA. Dr Lichtenstein earned his medical degree from the Mount Sinai School of Medicine in New York, New York, USA. He completed his internship and residency in internal medicine at Duke University Medical Center in Durham, North Carolina, USA. He served a fellowship in gastroenterology at the Hospital of the University of Pennsylvania School of Medicine.

His current research interests encompass investigational therapies for the treatment of ulcerative colitis and Crohn's disease. He has served as medical secretary for the American Board of Internal Medicine, gastroenterology section. He holds membership and committee positions in many professional societies at a national level, including: The American Gastroenterological Association, the American Society for Gastrointestinal Endoscopy, and the American College of Gastroenterology. He is also a member of the Crohn's and Colitis Foundation of America.

In addition to having served on the editorial boards of the journals Gastroenterology, American Journal of Gastroenterology, and Inflammatory Bowel Diseases, among others, he is the executive editor of a newly PubMed-indexed journal Gastroenterology and Hepatology, and serves as associate editor of Therapeutic Advances in Gastroenterology, The Physician and Sportsmedicine, and Clinical Investigation, and he is currently assistant editor-in-chief of the World Journal of Gastroenterology. An invited lecturer at the local, national, and international levels, Dr Lichtenstein is the author or coauthor of numerous peer-reviewed primary articles, chapters, letters, and editorials, and he has presented more than 250 abstracts and edited 18 books.

James Lindsay, PhD, BMBCh, FRCP, IBDLink Leadership
The Princess Grace Hospital
London, United Kingdom

Dr James Lindsay is a consultant in gastroenterology at Barts and the London NHS Trust. He trained in medicine at Cambridge and Oxford Universities, has a PhD from Imperial College and completed his gastroenterology training in London before commencing as a consultant in 2004. He specializes in the management of inflammatory bowel disease (IBD) and is clinical lead for the large IBD service at Barts and the London School of Medicine and Dentistry.

Dr Lindsay is a senior lecturer in gastroenterology and has a clinical research program investigating new therapies for ulcerative colitis and Crohn's disease. He chaired working groups for the European Consensus on the management of Crohn's disease and ulcerative colitis and is on the education committee of the European Crohn's and Colitis Organisation (ECCO). Additionally, he is a nationally accredited colonoscopist for bowel cancer screening.

Dr Lindsay is an e-learning ambassador for ECCO, and past chair of the ECCO education committee. He is the British Society of Gastroenterology (BSG) national societies representative to United European Gastroenterology.

He serves on the BSG IBD Clinical Trials Steering Group and is chief investigator for a series of investigator-led and commercial clinical trials in IBD. In addition, he collaborates with 2 translational research programs: one focuses on the antigen presentation within the mucosal immune system, and the other studies the role microRNA profiles to direct phenotype in IBD.

Gil Y. Melmed, MD, MS, IBDLink Leadership
Director, Clinical Inflammatory Bowel Disease
Cedars-Sinai Medical Center
Los Angeles, California, USA

Gil Y. Melmed, MD, MS, is director of clinical trials at the Clinical Inflammatory Bowel Disease (IBD) Center of Cedars-Sinai, and clinical assistant professor of medicine at David Geffen School of Medicine at the University of California, Los Angeles (UCLA). He is also director of clinical research in the Division of Gastroenterology at UCLA. Dr Melmed received his bachelor's degree from the University of Pennsylvania in Philadelphia, Pennsylvania, USA, and his medical degree from Albert Einstein College of Medicine in New York, New York. He completed his residency at Cedars-Sinai Medical Center and his gastroenterology fellowship at UCLA, where he also received a master's of science in clinical research.

Dr Melmed is board certified by the American Board of Internal Medicine in gastroenterology and internal medicine. His main clinical and research interests are clinical outcomes in IBD (Crohn's disease and ulcerative colitis), including health-related quality of life, post-operative outcomes, vaccination issues in patients with IBD, and why some patients with ulcerative colitis are subsequently diagnosed with Crohn's disease.

Dr Melmed’s research has been published in such journal as American Journal of Gastroenterology, Clinical Gastroenterology and Hepatology, and Clinical Gastroenterology and Hepatology.

Remo Panaccione, MD, IBDLink Leadership
Professor of Medicine
Director of IBD Clinic
University of Calgary
Calgary, Alberta, Canada

Remo Panaccione, MD, is currently Professor of Medicine and Director of the Inflammatory Bowel Disease Clinic at the University of Calgary in Alberta, Canada.

Dr Panaccione received his medical degree from the University of Western Ontario, London, Ontario, Canada. He completed his internal medicine and gastroenterology training at that institution, and is certified as a fellow of the Royal College of Physicians and Surgeons of Canada in both areas.

Dr Panaccione completed advanced training in IBD at the Mayo Clinic, Rochester, Minnesota, USA. He then joined the faculty of medicine of the University of Calgary.

Dr Panaccione has lectured across North America on various topics in IBD and has delivered more than 120 lectures in the last 5 years. He is the author of many peer-reviewed articles and book chapters on IBD. His special interest lies in the fields of advanced immunomodulation and biologic therapy. Dr Panaccione is a recognized authority on the use of biologics in Canada and has authored many guidelines on the use of biologics for the Canadian Association of Gastroenterology. He actively participates in clinical trials of new therapeutic agents in Crohn’s disease and ulcerative colitis. Dr Panaccione is currently medical director of the Calgary chapter of the Crohn's and Colitis Foundation of Canada and serves on the Medical Advisory Council of the parent organization. In 2014, he was awarded the Finkelstein award which is the highest award given by the organization for his contribution to the field.

Dr Panaccione has a great interest in medical education. He has been recognized as a gold star lecturer, small group leader, and clinical preceptor by the University of Calgary Cumming School of Medicine.

Dr Panaccione has been selected as the top post-graduate teacher in gastroenterology 3 times by the gastroenterology fellows of the university.

Laurent Peyrin-Biroulet, MD, PhD, IBDLink Leadership
Professor of Medicine
Nancy University Hospital
Vandoeuvre-lès-Nancy, France

Laurent Peyrin-Biroulet, MD, PhD, is full professor of medicine and head of the Inflammatory Bowel Disease (IBD) Unit (Inserm U954) at Nancy University Hospital in Vandoeuvre-lès-Nancy, France. After Dr Peyrin-Biroulet received his medical and doctoral degrees, he completed a post-doctoral fellowship at the IBD Centre in Lille, France. He worked in a research position at the Mayo Clinic in Rochester, Minnesota, USA, from 2008 to 2009.

Dr Peyrin-Biroulet’s work has been widely published. He is the author of more than 300 peer-reviewed and more than 200 non–peer-reviewed articles, and he is associate editor of Digestive and Liver Disease and a member of the editorial boards of Alimentary Pharmacology & Therapeutics, Journal of Crohn’s and Colitis, and Gut. Furthermore, Dr Peyrin-Biroulet serves as a reviewer for several international journals and is a staff contributor to the Selected Summaries Section of Gastroenterology. He joined the editorial team of the Cochrane IBD and Functional Bowel Disorders Review Group in 2014, and serves as councillor to the Immunology, Microbiology, and IBD Section of the American Gastroenterological Association Institute Council.

Notably, Dr Peyrin-Biroulet was coordinator for the development of the first IBD Disability Index, and proposed the first definitions of early Crohn’s disease and disease severity for IBD. He received a Rising Star Award in 2008 from the United European Gastroenterology Federation and was a member of the Federation’s Scientific Committee. He is vice president of Groupe d’Étude Thérapeutique des Affections Inflammatoires du Tube Digestif (GETAID) and president of the Scientific Committee of the Association François Aupetit.

In addition, Dr Peyrin-Biroulet is chair of the IBD Committee of Société Française d’Endoscopie Digestive and the Clinical Trials Task Force of the International Organization for the Study of IBD, and is general secretary of the European Crohn’s and Colitis Organisation (ECCO). He also contributed to the ECCO workshops on mucosal healing and malignancies, and participated in development of the ECCO guidelines on imaging and Crohn’s disease consensus.

David T. Rubin, MD, IBDLink Leadership
Joseph B. Kirsner Professor of Medicine
Chief, Section of Gastroenterology, Hepatology and Nutrition
Co-Director, Digestive Diseases Center
University of Chicago Medicine
Chicago, Illinois, USA

David T. Rubin, MD, a nationally recognized authority on digestive disease, and medical ethics, is section chief of gastroenterology, hepatology and nutrition at the University of Chicago Medicine in Illinois. Dr Rubin earned his medical degree with honors from the University of Chicago's Pritzker School of Medicine. He completed his residency in internal medicine, having been selected as chief resident, and fellowships in gastroenterology and clinical medical ethics at University of Chicago Medicine.

Dr Rubin, a professor of medicine at the University of Chicago, currently serves as co-director of the medical center's Digestive Diseases Center. He specializes in the treatment and assessment of digestive diseases. His clinical expertise includes inflammatory bowel diseases (Crohn’s disease and ulcerative colitis) and high-risk cancer syndromes. He is the principal investigator for multiple clinical research projects and trials of novel therapies.

He is a senior faculty scholar in the University of Chicago Medicine Bucksbaum Institute for Clinical Excellence, created to enhance the communication skills of doctors; an associate faculty member at the MacLean Center for Clinical Medical Ethics; and an associate investigator at the University of Chicago Medicine Comprehensive Cancer Center. He served as director of the gastroenterology fellowship program for 11 years, and, in 2012, was appointed head of educational programs for gastroenterology.

William J. Sandborn, MD, IBDLink Leadership
Chief, Division of Gastroenterology
Clinical Professor of Medicine
University of California San Diego School of Medicine
La Jolla, California, USA

William J. Sandborn, MD, received a medical degree and completed a residency in internal medicine at Loma Linda University in Loma Linda, California. His post-doctoral training also included a gastroenterology fellowship at the Mayo Clinic in Rochester, Minnesota. From 1993 to 2010, Dr Sandborn was on the faculty of the Mayo Clinic, rising to professor of medicine, vice chairman of the Division of Gastroenterology and Hepatology, and associate dean of research for intellectual property and industry relations. In 2011, he became a tenured professor of medicine, director of the inflammatory bowel disease center, and chief of the Division of Gastroenterology at the University of California San Diego in La Jolla, California. He is vice chair for clinical operations for the Department of Medicine, and a member of the UC San Diego Health System board of governors and of the clinical practice operations board (which oversees the clinical practice for the entire UC San Diego Health System).

Board certified in gastroenterology, Dr Sandborn holds membership in several professional societies, including the American Gastroenterological Association (AGA), the American College of Gastroenterology (ACG), and the Crohn’s & Colitis Foundation of America. Among his many honors, Dr Sandborn was elected to the International Organization for Inflammatory Bowel Disease and is past chairman of that organization. Dr Sandborn is a fellow of the AGA Institute, the ACG, and the American College of Physicians.

Dr Sandborn has published over 588 articles in peer-reviewed journals, including Lancet, New England Journal of Medicine, Annals of Internal Medicine, Journal of the American Medical Association, Gastroenterology, and Gut. Dr Sandborn’s research interests are clinical trials and clinical pharmacology related to inflammatory bowel disease. He is the principal investigator on several clinical studies focusing on the management of Crohn’s disease and ulcerative colitis.

Stefan Schreiber, MD, IBDLink Leadership
Professor of Medicine
Institute for Clinical Molecular Biology
University Hospital Schleswig-Holstein
Christian-Albrechts-Universität
Kiel, Germany

Stefan Schreiber, MD, PhD, is professor of medicine at the Institute for Clinical Molecular Biology of University Hospital Schleswig-Holstein in Kiel, Germany. He received his medical degree from the University of Hamburg in Hamburg, Germany. Prof Schreiber is a certified internist and gastroenterologist. He completed post-doctoral research fellowships in the Department of Gastroenterology at Washington University in St. Louis, Missouri, USA, and the University of Pennsylvania, Philadelphia, Pennsylvania, USA. He then became a junior faculty member in the Department of Gastroenterology at Charité–Universitätsmedizin Berlin in Berlin, Germany. Prof Schreiber assumed the position of associate professor in the Clinic for Internal Medicine I at Christian-Albrechts-Universität in Kiel. Prof Schreiber´s present position is full professor of medicine at Christian-Albrechts-Universität, where he also serves as director of the Clinic of Internal Medicine I and Head of the Institute for Clinical Molecular Biology.

Prof Schreiber is speaker for the German Research Foundation-funded Cluster of Excellence "Inflammation-at-Interfaces." His research interests include the molecular genetics and pathophysiology of chronic intestinal inflammation, clinical development of new therapies for IBD, and discovery of mechanisms that control aging.

Prof Schreiber is a member of several professional societies, including the American Gastroenterological Association, European Society for Clinical Investigation, German Crohn's Disease/Ulcerative Colitis Foundation (Scientific Committee), German Society of Internal Medicine, and German Society for Gastroenterology, Digestive and Metabolic Diseases. He has been an invited lecturer, and held chairmanships at multiple national and international meetings. Prof Schreiber is joint editor of several international journals in IBD and genetics, and has authored more than 800 original publications in various scientific journals.

Corey A. Siegel, MD, IBDLink Leadership
Associate Professor of Medicine and of The Dartmouth Institute for Health Policy & Clinical Practice
Geisel School of Medicine at Dartmouth
Hanover, New Hampshire, USA
Director, Inflammatory Bowel Disease Center
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire

Corey A. Siegel, MD, MS, is the Director of the Inflammatory Bowel Disease (IBD) Center at the Dartmouth-Hitchcock Medical Center in Lebanon, New Hampshire, and an Associate Professor of Medicine and of The Dartmouth Institute for Health Policy and Clinical Practice at the Geisel School of Medicine at Dartmouth.

Dr Siegel received his medical degree from Tufts University School of Medicine in Boston, Massachusetts in 1998. He completed his residency in internal medicine at the Dartmouth-Hitchcock Medical Center in Lebanon, New Hampshire. Dr. Siegel served as chief medical resident at Dartmouth from 2001-2002, where he also completed a fellowship in gastroenterology. From 2004-2005, he completed a fellowship in inflammatory bowel disease at Massachusetts General Hospital in Boston, Massachusetts.

Dr Siegel’s research interests include understanding risk/benefit tradeoffs in IBD, developing models to predict outcomes in Crohn’s disease, creating tools to facilitate shared decision-making, and improving the quality of care delivered to patients with IBD. He has been funded by the NIH, AHRQ and the Crohn’s and Colitis Foundation of America (CCFA) for this work. He has lectured nationally and internationally, and published numerous journal articles and book chapters on this and other topics in IBD. Dr Siegel is the founder of the BRIDGe group, an international research collaborative of IBD investigators. He has served as the co-chair of the CCFA Professional Education Committee, and is currently the co-chair of the CCFA’s Quality of Care Program (IBD Qorus). Dr Siegel was inducted into the International Organization for the Study of IBD (IOIBD) in 2013. He is on the editorial boards for Clinical Gastroenterology and Hepatology and Alimentary Pharmacology & Therapeutics, and serves as a reviewer for The American Journal of Gastroenterology, Clinical Gastroenterology and Hepatology, Journal of Crohn’s and Colitis, Inflammatory Bowel Diseases, The Cochrane Collaboration, and Gastroenterology. He lives in Hanover, New Hampshire with his wife and three boys.